Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bayreuth – page 2

40 clinical trials in Bayreuth, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bayreuth at a glance
40
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

40 trials in Bayreuth

Open in trial search

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Breast cancer metastatic

Recruiting

Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:GBG Forschungs GmbH

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Double hit lymphoma+7

Recruiting

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Universitaet Des Saarlandes

Plasma cell myeloma

Recruiting

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Colorectal cancer metastatic

Recruiting

Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Dementia Alzheimer's type

Not yet recruiting

Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Heidelberg University

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bayreuth

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on hematologic malignancies and solid tumors, including studies on chronic myeloid leukemia, multiple myeloma, and various types of breast cancer.

  • Leukemia Treatment Optimization
  • Breast Cancer Therapies
  • Colorectal Cancer Management

Research emphasizes novel drug combinations and treatment strategies to improve patient outcomes.

02 Neurological Disorders

Extensive research into multiple sclerosis treatments, including evaluations of new therapies and long-term safety studies of established medications.

  • MS Treatment Innovations
  • Spinal Cord Injury Therapies
  • Alzheimer's Disease Research

Studies focus on both relapsing and progressive forms of neurological conditions.

03 Therapeutic Approaches

Investigation of various treatment modalities including targeted therapies, immunotherapies, and combination treatments across multiple disease areas.

  • Novel Drug Combinations
  • Long-term Safety Studies
  • Treatment Optimization

Focus on developing personalized treatment strategies and improving patient outcomes.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.